Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalFRA:ZCY +1.48%58 Cyclically Adjusted PS Ratio is 0.72 as of Aug. 04, 2026, which is 70% below its 10-year median of 2.41. GuruFocus rates FRA:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.29. The stock has 4 warning signs investors should review. Among 359 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 61.56% on this metric.
The historical rank and industry rank for Cryo-Cell International's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:ZCY'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.65 Med: 2.41 Max: 4.64
Current: 0.78
During the past years, Cryo-Cell International's highest Cyclically Adjusted PS Ratio was 4.64. The lowest was 0.65. And the median was 2.41.
FRA:ZCY's Cyclically Adjusted PS Ratio is ranked better than 61.56% of 359
companies
in the Healthcare Providers & Services industry
Industry Median: 1.13
vs FRA:ZCY: 0.78
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Cryo-Cell International's adjusted revenue per share data for the three months ended in May. 2026 was €0.826. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.79 for the trailing ten years ended in May. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Cryo-Cell International (FRA:ZCY) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Cryo-Cell International Cyclically Adjusted PS Ratio Related Terms
Cryo-Cell International Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International Cyclically Adjusted PS Ratio Chart
FRA:ZCY vs EHSI, PIII, CCM: Cyclically Adjusted PS Ratio Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Cyclically Adjusted PS Ratio falls into.
Cryo-Cell International Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.72 mean?
Cryo-Cell International (FRA:ZCY) has a Cyclically Adjusted PS Ratio of 0.72 as of Aug. 04, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cryo-Cell International and its competitors. This is 70% below median its historical median of 2.41. Over the past decade, Cryo-Cell International's Cyclically Adjusted PS Ratio has ranged from 0.65 to 4.64. According to the industry distribution chart, Cryo-Cell International ranks #138 out of 359 companies in the Healthcare Providers & Services industry, placing it in the top 38.4%.
Is Cryo-Cell International's Cyclically Adjusted PS Ratio too high?
Cryo-Cell International's current Cyclically Adjusted PS Ratio of 0.72 is 70% below median its 10-year median of 2.41. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 4.64. The Healthcare Providers & Services industry median Cyclically Adjusted PS Ratio is 1.13. Cryo-Cell International's value of 0.72 is 36.3% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #138 out of 359 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Cyclically Adjusted PS Ratio compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #138 out of 359 companies for Cyclically Adjusted PS Ratio. This puts Cryo-Cell International in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.13. Cryo-Cell International's value of 0.72 is 36.3% below this benchmark. Historically, Cryo-Cell International's own Cyclically Adjusted PS Ratio has ranged from 0.65 to 4.64 over the past decade. While the company's 10-year median is 2.41 vs. the industry median of 1.13, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Healthcare Providers & Services company?
The median Cyclically Adjusted PS Ratio among Healthcare Providers & Services companies is 1.13, based on 359 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Cyclically Adjusted PS Ratio of 0.72 is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Cyclically Adjusted PS Ratio is 1.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Cyclically Adjusted PS Ratio is 0.72, which is 70% below median its own 10-year median of 2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Cryo-Cell International (FRA:ZCY) has a current Cyclically Adjusted PS Ratio of 0.72. The stock's GF Value™ is €4.29, compared to a current price of €2.74 — trading 36.1% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.72, which is 70% below median its 10-year median of 2.41 and 36.3% below the Healthcare Providers & Services industry median of 1.13. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Cyclically Adjusted PS Ratio is 0.72 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.74 is trading 36.1% below its estimated GF Value™ of €4.29.
Key valuation signals for FRA:ZCY:
Cyclically Adjusted PS Ratio: 0.72 (70% below median its 10-year median of 2.41)
GF Value™: €4.29 vs. price of €2.74 (36.1% below fair value)
Industry Position: 36.3% below the Healthcare Providers & Services median (#138 of 359)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for FRA:ZCY
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
